Compare Johnson & Johnson (JNJ) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs JPMorgan Ultra Short Income ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while JPMorgan Ultra Short Income ETF trades at $50.3 (market cap $42.37B). The key difference: Johnson & Johnson is far larger — about 14.6× JPMorgan Ultra Short Income ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while JPMorgan Ultra Short Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and JPMorgan Ultra Short Income ETF for 47 Days on average.
| JNJ | JPST | |
|---|---|---|
Market Cap | $618.09B | $42.37B |
Volume | 6,050,983 | 7,889,185 |
Sector | Health | Fixed Income |
52-Week High | $278.43 | $50.78 |
52-Week Low | $186.00 | $50.22 |
Typical Hold Time | 129 Days | 47 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
JPST trades at $50.27 with no recent price movement, showing stability amid bearish technical signals from moving averages. The ETF maintains consistent dividend distributions of $0.17 monthly, positioning as a cash-equivalent alternative. Recent news highlights institutional position adjustments and growing investor interest in ultra-short income strategies as rates rise.
The outlook remains stable for income-focused investors seeking minimal volatility. Key risks include interest rate sensitivity and active management performance versus peers. Recent institutional selling activity suggests some profit-taking despite the fund's role in portfolio cash management strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
